EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Application of e-Mail in Successful Desensitization to Allopurinol:

Khalid O. Bawakid, Majdy M.A. Qutub, Moufa M.S. Tayeb, Emad A. Koshak

Saudi Journal of Internal Medicine · 2011

DOI: 10.32790/sjim.1.2.7 ↗
AbstractBibliografische Angaben

Abstract

Allopurinol hypersensitivity can develop in 2% of cases (severe in 0.4%). If no alternative, oral desensitization is effective but it is associated with difficulties in monitoring and safety. A 65-years old Saudi male presented to allergy clinic at King Abdulaziz University Hospital as a case of type I hypersensitivity to Allopurinol. Phase I desensitization was conducted in the clinic over 4 hours by increasing doses of oral Allopurinol, starting from 0.01 mg up to 1 mg. Phase II desensitization was performed at home over 5 weeks with increasing doses from 1 mg up to 100 mg/day (pharmaceutical dose). Daily e-Mail messages were very helpful in patient monitoring by providing proper advice. Minor allergy symptoms, like itching and rash, resolved with oral antihistamines and maintaining the same dose until clear. To our knowledge, this is the first case report of using e-Mail as an effective tool for monitoring successful oral drug desensitization.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →